On Tuesday, February 25, 2025, leading researchers in the field of Alzheimer’s disease will convene for the Semi-Annual Epstein Family Research Collaboration Investigator’s Meeting in San Diego, California.
The Epstein Family Alzheimer’s Research Collaboration is a groundbreaking collaboration established to unite the world-class expertise of the University of Southern California and the University of California, San Diego. Tuesday’s meeting serves as a critical platform for advancing Alzheimer’s research through partnership, data sharing, and innovative scientific exploration.
Dr. Paul Aisen, founding director of ATRI, will deliver opening remarks alongside Judy Pa, Co-Director of the Alzheimer’s Disease Cooperative Study.
The meeting's sessions will involve critical conversations around diverse recruitment efforts, data sharing, and also the Powder for Pennies program, an initiative designed to accelerate the testing of existing and repurposed drugs for the treatment of Alzheimer’s disease.
Embodying the meeting's spirit of innovation and collaboration, Gustavo Jimenez-Maggiora will present his session, "Data and Biospecimen Sharing Infrastructure." Reflecting on the significance of the meeting, he noted, "With the generous support of the Epstein Foundation, this meeting convenes some of Southern California's leading Alzheimer's researchers, including scientific leaders from USC and ATRI, to explore cutting-edge research, identify novel therapeutic targets, and share valuable data to accelerate the development of effective treatments for Alzheimer's disease."
The Semi-Annual Epstein Family Research Collaboration Investigator’s Meeting underscores ATRI’s commitment to driving joint research initiatives, fostering scientific innovation, and accelerating the development of effective Alzheimer’s therapies. It serves as an essential gathering for leading experts to exchange ideas, share insights, and pave the way for future advancements in Alzheimer’s research.
Highlighting the broad impact of this event, ATRI Medical Director Michael Rafii remarked, "This meeting isn’t just a gathering, it’s a powerful platform for pioneering innovation, sharing new data, and forging collaborative bonds that will accelerate our collective journey toward understanding and ultimately conquering Alzheimer’s disease."